ArticleAging medicine (Milton (N.S.W))2025
Effect of Bazi Bushen Capsule on D-Galactose-Induced Human Endothelial Cell Senescence Through PI3K/Akt/eNOS Signaling Pathway.
Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bazi Bushen Capsule restores fertility by targeting mitochondrial health in aging endometrium.iMeta · 2026Article
- Research status and molecular mechanisms of disulfidptosis in cardiovascular diseases (Review).Molecular medicine reports · 2026Review
- Ginsenoside Rg1 delays the senescence of adipose-derived stem cells: network pharmacology and experimental validation.Hereditas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: BaZi BuShen capsule (BZBS) is a Chinese herbal prescription with the function of nourishing the kidney, replenishing essence, and combating aging. This study aims to investigate the effects of BZBS on aging endothelial cells and to elucidate the underlying mechanisms. Methods: An aging human brain microvascular endothelial cells (HBMECs) model was established using D-galactose (D-gal) for 24 h. The efficacy of the model was evaluated by the positive rate of senescence-associated β-galactosidase (SA-β-Gal) staining. The treatment was administered using drug-containing serum of BZBS. The experimental groups comprised the following: Control, Model, and groups treated with drug-containing serum at low (BZBSL), medium (BZBSM), and high (BZBSH) doses of BZBS, in addition to a pathway inhibitor group (LY294002 [5 μM/L]). Western blotting and immunofluorescence assays were conducted to evaluate the expression levels of proteins. Nitric oxide (NO) levels in the cells were detected using an Assay Kit. The experiments were independently repeated five times. Results: D-gal significantly elevated the SA-β-Gal positive rate in HBMECs. Intervention with BZBS significantly reduced the percentage of SA-β-Gal positive cells ( Conclusions: Our findings indicate that BZBS can mitigate D-gal-induced aging in HBMECs by activating the PI3K/Akt/eNOS signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.